Abstract
Investigating the most likely causal variants identified by fine-mapping analyses may improve the power to detect gene–environment interactions. We assessed the interplay between 70 single nucleotide polymorphisms identified by genetic fine-scale mapping of susceptibility loci and 11 epidemiological breast cancer risk factors in relation to breast cancer. Analyses were conducted on up to 58,573 subjects (26,968 cases and 31,605 controls) from the Breast Cancer Association Consortium, in one of the largest studies of its kind. Analyses were carried out separately for estrogen receptor (ER) positive (ER+) and ER negative (ER–) disease. The Bayesian False Discovery Probability (BFDP) was computed to assess the noteworthiness of the results. Four potential gene–environment interactions were identified as noteworthy (BFDP < 0.80) when assuming a true prior interaction probability of 0.01. The strongest interaction result in relation to overall breast cancer risk was found between CFLAR-rs7558475 and current smoking (ORint = 0.77, 95% CI: 0.67–0.88, pint = 1.8 × 10−4). The interaction with the strongest statistical evidence was found between 5q14-rs7707921 and alcohol consumption (ORint =1.36, 95% CI: 1.16–1.59, pint = 1.9 × 10−5) in relation to ER– disease risk. The remaining two gene–environment interactions were also identified in relation to ER– breast cancer risk and were found between 3p21-rs6796502 and age at menarche (ORint = 1.26, 95% CI: 1.12–1.43, pint =1.8 × 10−4) and between 8q23-rs13267382 and age at first full-term pregnancy (ORint = 0.89, 95% CI: 0.83–0.95, pint = 5.2 × 10−4). While these results do not suggest any strong gene–environment interactions, our results may still be useful to inform experimental studies. These may in turn, shed light on the potential interactions observed.
Original language | English (US) |
---|---|
Pages (from-to) | 1830-1840 |
Number of pages | 11 |
Journal | International Journal of Cancer |
Volume | 141 |
Issue number | 9 |
DOIs | |
State | Published - Nov 1 2017 |
Keywords
- Breast Cancer Association Consortium
- breast cancer
- gene–environment
- interaction
- single nucleotide polymorphism
ASJC Scopus subject areas
- Oncology
- Cancer Research
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Gene–environment interactions involving functional variants: Results from the Breast Cancer Association Consortium'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Gene–environment interactions involving functional variants : Results from the Breast Cancer Association Consortium. / Barrdahl, Myrto; Rudolph, Anja; Hopper, John L. et al.
In: International Journal of Cancer, Vol. 141, No. 9, 01.11.2017, p. 1830-1840.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Gene–environment interactions involving functional variants
T2 - Results from the Breast Cancer Association Consortium
AU - Barrdahl, Myrto
AU - Rudolph, Anja
AU - Hopper, John L.
AU - Southey, Melissa C.
AU - Broeks, Annegien
AU - Fasching, Peter A.
AU - Beckmann, Matthias W.
AU - Gago-Dominguez, Manuela
AU - Castelao, J. Esteban
AU - Guénel, Pascal
AU - Truong, Thérèse
AU - Bojesen, Stig E.
AU - Gapstur, Susan M.
AU - Gaudet, Mia M.
AU - Brenner, Hermann
AU - Arndt, Volker
AU - Brauch, Hiltrud
AU - Hamann, Ute
AU - Mannermaa, Arto
AU - Lambrechts, Diether
AU - Jongen, Lynn
AU - Flesch-Janys, Dieter
AU - Thoene, Kathrin
AU - Couch, Fergus J.
AU - Giles, Graham G.
AU - Simard, Jacques
AU - Goldberg, Mark S.
AU - Figueroa, Jonine
AU - Michailidou, Kyriaki
AU - Bolla, Manjeet K.
AU - Dennis, Joe
AU - Wang, Qin
AU - Eilber, Ursula
AU - Behrens, Sabine
AU - Czene, Kamila
AU - Hall, Per
AU - Cox, Angela
AU - Cross, Simon
AU - Swerdlow, Anthony
AU - Schoemaker, Minouk J.
AU - Dunning, Alison M.
AU - Kaaks, Rudolf
AU - Pharoah, Paul D.P.
AU - Schmidt, Marjanka
AU - Garcia-Closas, Montserrat
AU - Easton, Douglas F.
AU - Milne, Roger L.
AU - Chang-Claude, Jenny
N1 - Funding Information: sponsor: NHMRC; Grant number: 209057, 251553, 504711; Grant sponsor: Quebec Breast Cancer Foundation; Grant sponsor: CIHR Team in Familial Risks of Breast Cancer; Grant sponsor: Ministry of Economic Development, Innovation and Export Trade; Grant number: # PSR-SIIRI-701; Grant sponsor: Intramural Research Funds, National Cancer Institute, Department of Health and Human Services, USA; Grant sponsor: M€arit and Hans Rausings Initiative Against Breast Cancer; Grant sponsor: Cancer Risk Prediction Center CRisP; Grant sponsor: Linnaeus Centre; Grant sponsor: Swedish Research Council; Grant number: 70867902; Grant sponsor: Agency for Science, Technology and Research of Singapore (A*STAR); Grant sponsor: US National Institute of Health (NIH); Grant sponsor: Susan G. Komen Breast Cancer Foundation; Grant sponsor: Yorkshire Cancer Research; Grant number: S295, S299, S305PA; Grant sponsor: Sheffield Experimental Cancer Medicine Centre; Grant sponsor: UK National Institute for Health Research Biomedical Research Centre, University of Cambridge; Grant sponsor: Cancer Research UK; Grant sponsor: Breast Cancer Now; Grant sponsor: Institute of Cancer Research (ICR), London; Grant sponsor: Cancer Care Ontario; Grant number: U01 CA69467; Grant sponsor: National Cancer Institute; Grant number: UM1 CA164920; Grant sponsor: Acción Estratégica de Salud del Instituto de Salud Carlos III; Grant number: FIS PI12/02125 , PI13/01136 DOI: 10.1002/ijc.30859 History: Received 7 Nov 2016; Accepted 11 Apr 2017; Online 3 July 2017 This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. Correspondence to: Jenny Chang-Claude, Im Neuenheimer Feld 581, 69120 Heidelberg, Germany, Tel.: 149-6221-42-2373, Fax: 149-6221-42-2203, E-mail: j.chang-claude@dkfz.de Funding Information: Key words: breast cancer, single nucleotide polymorphism, Breast Cancer Association Consortium, gene–environment, interaction Additional Supporting Information may be found in the online version of this article. Conflicts of Interest J.S. is Chairholder of the Canada Research Chair in Oncogenetics. J.L.H. is a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellow. M.C.S. is a NHMRC Senior Research Fellow. Fergus J. Couch received research support from GRAIL Inc. Grant sponsor: Cancer Research UK; Grant number: C1287/A16563, C1287/A10118, C1287/A10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565; Grant sponsor: European Union’s Horizon 2020 Research and Innovation Programme; Grant number: 634935, 633784; Grant sponsor: European Community’s Seventh Framework Programme; Grant number: 223175 (HEALTHF2-2009-223175); Grant sponsor: National Institutes of Health; Grant number: CA128978; Grant sponsor: Post-Cancer GWAS initiative; Grant number: 1U19 CA148537, 1U19 CA148065, 1U19 CA148112; Grant sponsor: Department of Defence; Grant number: W81XWH-10-1-0341; Grant sponsor: Canadian Institutes of Health Research (CIHR); Grant number: CRN-87521; Grant sponsor: Komen Foundation for the Cure; Grant sponsor: Breast Cancer Research Foundation; Grant sponsor: Ovarian Cancer Research Fund; Grant sponsor: United States National Cancer Institute, National Institutes of Health (NIH); Grant number: RFA-CA-06-503; Grant sponsor: Breast Cancer Family Registry (BCFR), Cancer Care Ontario; Grant number: U01 CA69467; Grant sponsor: Cancer Prevention Institute of California; Grant number: U01 CA69417; Grant sponsor: University of Melbourne; Grant number: U01 CA69638; Grant sponsor: National Cancer Institute; Grant number: UM1 CA164920; Grant sponsor: National Health and Medical Research Council of Australia; Grant sponsor: New South Wales Cancer Council; Grant sponsor: Victorian Health Promotion Foundation; Grant sponsor: Victorian Breast Cancer Research Consortium; Grant sponsor: Dutch Cancer Society; Grant number: NKI 2007-3839; 2009-4363; Grant sponsor: Dutch Government; Grant number: NWO 184.021.007; Grant sponsor: Dutch National Genomics Initiative; Grant sponsor: ELAN-Fond; Grant sponsor: Acción Estratégica de Salud del Instituto de Salud Carlos III; Grant number: FIS PI12/02125, PI13/01136; Grant sponsor: KAU; Grant number: 1-117-1434-HiCi; Grant sponsor: Botin Foundation’s Fund; Grant sponsor: Programa Grupos Emergentes, Cancer Genetics Unit, CHUVI Vigo Hospital, Instituto de Investigación Sanitaria Galicia Sur (IISGS), Instituto de Salud Carlos III, Spain; Grant sponsor: Consellería de Industria Programa Sectorial de Investigación Aplicada, PEME I 1 D e I 1 D Suma del Plan Gallego de Investigación, Desarrollo e Innovación Tecnológica de la Consellería de Industria de la Xunta de Galicia, Spain; Grant number: 10CSA012E; Grant sponsor: Fomento de la Investigación Clínica Independiente, Ministerio de Sanidad, Servicios Sociales e Igualdad, Spain; Grant number: EC11-192; Grant sponsor: Grant FEDER-Innterconecta, Ministerio de Economia y Competitividad, Xunta de Galicia, Spain; Grant sponsor: Fondation de France; Grant sponsor: Institut National du Cancer (INCa); Grant sponsor: Ligue Nationale contre le Cancer; Grant sponsor: Ligue contre le Cancer Grand Ouest; Grant sponsor: Agence Nationale de SécuritéSanitaire (ANSES); Grant sponsor: Agence Nationale de la Recherche (ANR); Grant sponsor: Chief Physician Johan Boserup and Lise Boserup Fund; Grant sponsor: Danish Medical Research Council; Grant sponsor: Herlev Hospital; Grant sponsor: American Cancer Society; Grant sponsor: Baden Wu€rttemberg Ministry of Science, Research and Arts; Grant sponsor: German Cancer Aid (Deutsche Krebshilfe); Grant sponsor: Federal Ministry of Education and Research (BMBF), Germany; Grant number: 01KW9975/5, 01KW9976/8, 01KW9977/0, 01KW0114; Grant sponsor: Robert Bosch Foundation, Stuttgart; Grant sponsor: Deutsches Krebsforschungszentrum (DKFZ), Heidelberg; Grant sponsor: Institute for Prevention and Occupational Medicine of the German Social Accident Insurance; Grant sponsor: Institute of the Ruhr University Bochum (IPA), Bochum; Grant sponsor: Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany; Grant sponsor: Government Funding (EVO) of Kuopio University Hospital; Grant sponsor: Cancer Fund of North Savo; Grant sponsor: Finnish Cancer Organizations; Grant sponsor: University of Eastern Finland; Grant sponsor: Stichting tegen Kanker; Grant number: 232-2008, 196-2010; Grant sponsor: FWO; Grant number: KULPFV/10/016-SymBioSysII; Grant sponsor: KULPFV; Grant number: 70-2892-BR I, 106332, 108253, 108419, 110826, 110828; Grant sponsor: Hamburg Cancer Society; Grant sponsor: NIH Specialized Program of Research Excellence (SPORE) in Breast Cancer; Grant number: CA116201; Grant sponsor: David F. and Margaret T.; Grant sponsor: Grohne Family Foundation; Grant sponsor: VicHealth; Grant sponsor: Cancer Council Victoria; Grant Publisher Copyright: © 2017 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC
PY - 2017/11/1
Y1 - 2017/11/1
N2 - Investigating the most likely causal variants identified by fine-mapping analyses may improve the power to detect gene–environment interactions. We assessed the interplay between 70 single nucleotide polymorphisms identified by genetic fine-scale mapping of susceptibility loci and 11 epidemiological breast cancer risk factors in relation to breast cancer. Analyses were conducted on up to 58,573 subjects (26,968 cases and 31,605 controls) from the Breast Cancer Association Consortium, in one of the largest studies of its kind. Analyses were carried out separately for estrogen receptor (ER) positive (ER+) and ER negative (ER–) disease. The Bayesian False Discovery Probability (BFDP) was computed to assess the noteworthiness of the results. Four potential gene–environment interactions were identified as noteworthy (BFDP < 0.80) when assuming a true prior interaction probability of 0.01. The strongest interaction result in relation to overall breast cancer risk was found between CFLAR-rs7558475 and current smoking (ORint = 0.77, 95% CI: 0.67–0.88, pint = 1.8 × 10−4). The interaction with the strongest statistical evidence was found between 5q14-rs7707921 and alcohol consumption (ORint =1.36, 95% CI: 1.16–1.59, pint = 1.9 × 10−5) in relation to ER– disease risk. The remaining two gene–environment interactions were also identified in relation to ER– breast cancer risk and were found between 3p21-rs6796502 and age at menarche (ORint = 1.26, 95% CI: 1.12–1.43, pint =1.8 × 10−4) and between 8q23-rs13267382 and age at first full-term pregnancy (ORint = 0.89, 95% CI: 0.83–0.95, pint = 5.2 × 10−4). While these results do not suggest any strong gene–environment interactions, our results may still be useful to inform experimental studies. These may in turn, shed light on the potential interactions observed.
AB - Investigating the most likely causal variants identified by fine-mapping analyses may improve the power to detect gene–environment interactions. We assessed the interplay between 70 single nucleotide polymorphisms identified by genetic fine-scale mapping of susceptibility loci and 11 epidemiological breast cancer risk factors in relation to breast cancer. Analyses were conducted on up to 58,573 subjects (26,968 cases and 31,605 controls) from the Breast Cancer Association Consortium, in one of the largest studies of its kind. Analyses were carried out separately for estrogen receptor (ER) positive (ER+) and ER negative (ER–) disease. The Bayesian False Discovery Probability (BFDP) was computed to assess the noteworthiness of the results. Four potential gene–environment interactions were identified as noteworthy (BFDP < 0.80) when assuming a true prior interaction probability of 0.01. The strongest interaction result in relation to overall breast cancer risk was found between CFLAR-rs7558475 and current smoking (ORint = 0.77, 95% CI: 0.67–0.88, pint = 1.8 × 10−4). The interaction with the strongest statistical evidence was found between 5q14-rs7707921 and alcohol consumption (ORint =1.36, 95% CI: 1.16–1.59, pint = 1.9 × 10−5) in relation to ER– disease risk. The remaining two gene–environment interactions were also identified in relation to ER– breast cancer risk and were found between 3p21-rs6796502 and age at menarche (ORint = 1.26, 95% CI: 1.12–1.43, pint =1.8 × 10−4) and between 8q23-rs13267382 and age at first full-term pregnancy (ORint = 0.89, 95% CI: 0.83–0.95, pint = 5.2 × 10−4). While these results do not suggest any strong gene–environment interactions, our results may still be useful to inform experimental studies. These may in turn, shed light on the potential interactions observed.
KW - Breast Cancer Association Consortium
KW - breast cancer
KW - gene–environment
KW - interaction
KW - single nucleotide polymorphism
UR - http://www.scopus.com/inward/record.url?scp=85028634707&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028634707&partnerID=8YFLogxK
U2 - 10.1002/ijc.30859
DO - 10.1002/ijc.30859
M3 - Article
C2 - 28670784
AN - SCOPUS:85028634707
SN - 0020-7136
VL - 141
SP - 1830
EP - 1840
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 9
ER -